Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07668401
Starting soon Phase 3

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

NCT07668401 · tracked via the Priya Life Science South Korea tracker
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Started
2027-01-07
Last updated
2026-08-24

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

Zenagamtide →Placebo ( matched to Zenagamtide)

Zenagamtide: Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Placebo ( matched to Zenagamtide): Placebo matched to Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Study summary

The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.

Primary outcome measure(s)

  • Relative change in body weight — From baseline (week 0) to week 80
    Measured as percentage of body weight.

Trial sites (44)

FacilityCityRegionStatus
Nirmal Hospital Pvt. Ltd. Surat Gujarat
SSG Hospital, Baroda Vadodara Gujarat
Karnataka Medical College and Research Institute Hubbali Karnataka
Government Medical College, Kozhikode Kozhikode Kerala
TOTALL Diabetes Hormone Institute Indore Madhya Pradesh
Shree Mahalaxmi DIATONE Institute Kohlapur Maharashtra
Excel Endocrine Centre Kolhāpur Maharashtra
BSES MG hospital Mumbai Maharashtra
All India Institute of Medical Sciences (AIIMS), Nagpur Nagpur Maharashtra
Shalini Tai Meghe Hospital and Research Center Nagpur Maharashtra
Vijan Hospital & Research Centre Nashik Maharashtra
Grant Medical Foundation Ruby Hall Clinic Pune Maharashtra
Chellaram Diabetes Institute Pune Maharashtra
Maulana Azad Medical College Delhi New Delhi
Madras Diabetes Research Foundation Chennai Tamil Nadu
Christian Medical College Hospital, Vellore Vellore Tamil Nadu
Diabetes Research Center, Hyderabad Hyderabad Telangana
Osmania General Hospital Hyderabad Telangana
All India Institute of Medical Science (AIIMS), Guwahati Assam India
SMS Hospital Jaipur India
GMERS Medical college and hospital Vadodara India
OCROM Clinic_Internal medicine Suita-shi Osaka
Kindai University Hospital_Department of Endocrinology, Metabolism and Diabetes Sakai-shi, Osaka Japan
Medical Corporation Shinanokai Shinanozaka Clinic_Internal Medicine Shinjuku-ku, Tokyo Japan
Tokyo-Eki Center-building Clinic_Internal Medicine Tokyo Japan
Fukuwa Clinic_Internal Medicine Tokyo Japan
ToCROM Clinic_Internal Medicine Tokyo Japan
Hospital Canselor Tuanku Muhriz UKM Cheras Kuala Lumpur
University Malaya Medical Centre Lembah Pantai Kuala Lumpur
Hospital Miri Miri Sarawak
Hospital Melaka Malacca Malaysia
Hospital Putrajaya Putrajaya Malaysia
Seoul National University Bundang Hospital_Endocrinology Seoungnam-si Gyeonggi-do
Ajou University Hospital_Family Medicine Suwon Gyeonggi-do
Pusan National University Yangsan Hospital_Family Medicine Yangsan Gyeongsangnam-do
Kyungpook National University Hospital_Family Medicine Daegu South Korea
Seoul National University Hospital_Family Medicine Seoul South Korea
Severance Hospital, Yonsei University Health System_Family Medicine Seoul South Korea
Konkuk University Medical Center_Endocrinology Seoul South Korea
Ramathibodi Hospital Bangkok Thailand

+ 4 more sites — see the full list on the official registry below.

More Novo Nordisk A/S trials in South Korea

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy Recruiting
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea Enrolling by invitation
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 Active, not recruiting
WEgovy Real World Assessment of Weight Loss in Korea Enrolling by invitation
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow Active, not recruiting

Other trials for the same condition

WEgovy Real World Assessment of Weight Loss in Korea Enrolling by invitation
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Active, not recruiting
Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study Enrolling by invitation
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07668401 on ClinicalTrials.gov ↗ ← All trials in South Korea